# Mary A. Dwyer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mary-a-dwyer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,243 |
| Field | Lymphoma Diagnosis and Treatment |
| h-index | 62 |
| i10-index | 86 |
| Last Known Institution | National Comprehensive Cancer Network |
| OpenAlex ID | https://openalex.org/A5111880821 |
| Works | 116 |

## Researcher papers

Showing 12 of 14.

- [Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/genetic-familial-high-risk-assessment-breast-ovarian-and-pancreatic-version-2/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-breast-and/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-breast-ovarian/)
- [NCCN Guidelines® Insights: Breast Cancer, Version 4.2023](https://scholariq.org/papers/nccn-guidelines-insights-breast-cancer-version-4-2023/)
- [Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/management-of-immunotherapy-related-toxicities-version-1-2022-nccn-clinical/)
- [NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022](https://scholariq.org/papers/nccn-guidelines-insights-ovarian-cancer-version-3-2022/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-colorectal-2/)
- [NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022](https://scholariq.org/papers/nccn-guidelines-insights-bladder-cancer-version-2-2022/)
- [Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/bladder-cancer-version-5-2017-nccn-clinical-practice-guidelines-in-oncology/)
- [Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/genetic-familial-high-risk-assessment-colorectal-version-1-2016-nccn-clinical/)
- [NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017](https://scholariq.org/papers/nccn-guidelines-insights-genetic-familial-high-risk-assessment-colorectal/)

## Researcher topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Colorectal Cancer Screening and Detection](https://scholariq.org/topics/colorectal-cancer-screening-and-detection/)
- [Wnt/β-catenin signaling in development and cancer](https://scholariq.org/topics/wnt-catenin-signaling-in-development-and-cancer-2/)

## Researcher university

- [National Comprehensive Cancer Network](https://scholariq.org/institutions/national-comprehensive-cancer-network/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.